Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 228

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 228
---
 best currently available estimates and judgments by managements as to the expected
future results of operations and financial condition of the Companies to which such analyses or forecasts relate in all respects material
to our analysis. We are not legal, regulatory or tax experts and have relied on the assessments made by advisors to the Company with respect
to such issues. We have further assumed that all material governmental, regulatory or other consents and approvals necessary for the consummation
of the Transaction will be obtained without any adverse effect on the Merger Partner or the Company or on the contemplated benefits of
the Transaction.

Our opinion is necessarily
based on economic, market and other conditions as in effect on, and the information made available to us as of, the date hereof. It should
be understood that subsequent developments may affect this opinion and that we do not have any obligation to update, revise, or reaffirm
this opinion. Our opinion is limited to the fairness, from a financial point of view, of the exchange ratio in the proposed transaction.

On the basis of and subject
to the foregoing, it is our opinion as of the date hereof that the exchange ratio in the proposed transaction is fair, from a financial
point of view.

This opinion does not constitute
a recommendation to any shareholder of the Companies as to how such shareholder should vote with respect to the transaction or any other
matter. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose whatsoever
except with our prior written approval. This opinion may be reproduced in full in any proxy statement mailed to shareholders of the Companies
but may not otherwise be disclosed publicly in any manner without our prior written approval.

Moore Financial Consulting

| Moore Financial Consulting |

ANNEX E

<div align='center'>EXCLUSIVE LICENSE AGREEMENT</div>

THIS EXCLUSIVE LICENSE AGREEMENT(this “Agreement”) is entered into as of March 3, 2025 (the “Effective Date”), by and between MIRALOGX LLC, a Florida limited liability company located at 3014 West Palmira Ave., Suite 302, Tampa, FL 33629 (“Licensor”), and TELI PHARMACEUTICALS INC., a Florida corporation having its principal place of business at 3014 West Palmira Ave., Suite 302, Tampa, FL 33629 (“Licensee”). Licensor and Licensee are each herein referred to as “Party” and collectively as the “Parties.”

WHEREAS